Ugo Amaldi

Learn More
In 1991 the author involved the Italian institute of nuclear physics (INFN) in R&D work in the field of hadrontherapy. In 1992 the TERA Foundation was created with the purpose of forming and employing people fully devoted to the design, promotion and construction of hadrontherapy centres in Italy and in Europe. The present contribution describes the main(More)
As initial remark to this opening talk of EPAC2000 it can cursorily be said that particle accelerators are certainly important because the salaries and pension funds of the participants to this Conference depend on the existence, the running and the construction of accelerators. More seriously, it is useful to consider the three main uses of the primary and(More)
The field of hadrontherapy has grown rapidly in recent years. At present the therapeutic beam is provided by a cyclotron or a synchrotron, but neither cyclotrons nor synchrotrons present the best performances for hadrontherapy. The new generation of accelerators for hadrontherapy should allow fast active energy modulation and have a high repetition rate, so(More)
On-line verification of the delivered dose during proton and carbon ion radiotherapy is currently a very desirable goal for quality assurance of hadron therapy treatment plans. In-beam positron emission tomography (ibPET), which can provide an image of the β+ activity induced in the patient during irradiation, which in turn is correlated to the range of the(More)
  • 1